918659-56-0

Basic information

• Product Name: Chaetominine
• Synonyms: Chaetominine;(2S,4R,5aS,9cS)-4,5,5a,9c-Tetrahydro-5a-hydroxy-2-methyl-4-(4-oxo-3(4H)-quinazolinyl)-3H-2a,9b-diazacyclopenta[jk]fluorene-1,3(2H)-dione;Chaetominine (-)-Chaetominine;(2S,2a1S,4R,5AS)-5a-hydroxy-2-methyl-4-(4-oxoquinazolin-3(4H)-yl)-2a1,4,5,5a-tetrahydro-1H-2a
• CAS NO: 918659-56-0
• Molecular Formula: C22H18N4O4
• Molecular Weight: 402.41
• EINECS: -0
• Mol File: 918659-56-0.mol
• Article Data: 9

Chemical Properties

• Melting Point: 164℃
• Appearance: /
• Density: 1.63
• CAS DataBase Reference: Chaetominine(CAS DataBase Reference)
• NIST Chemistry Reference: Chaetominine(918659-56-0)
• EPA Substance Registry System: Chaetominine(918659-56-0)

Safety Data

• Hazardous Substances Data: 918659-56-0(Hazardous Substances Data)

Usage

Description

(–)-Chaetominine is a cytotoxic alkaloid originally isolated from Chaetomium sp. IFB-E015. It inhibits the growth of K562 leukemia and SW1116 colon cancer cells (IC50s = 20 and 28 nM, respectively). (–)-Chaetominine induces apoptosis of K562 cells via upregulation of the Bax/Bcl-2 ratio, decreasing mitochondrial membrane potential, inducing mitochondrial cytochrome C release, and activation of caspase-3 and caspase-9. It also decreases doxorubicin efflux mediated by multidrug resistance-associated protein 1 (MRP1) and restores sensitivity to doxorubicin in resistant K562 cells.

Upstream product

• 72144-94-6 3-indol-3-yl-2-(4-oxo-4H-quinazolin-3-yl)-propionic acid 
• 85612-29-9 N_b-(2-aminobenzoyl)-L-tryptophan methyl ester 
• 1190112-03-8 C₁₉H₁₅N₃O₃ 
• 205042-94-0 N-(2-aminobenzoyl)-D-tryptophan methyl ester 
• 7524-52-9 (S)-tryptophan methyl ester hydrochloride 
• 118-48-9 isatoic anhydride 
• 14907-27-8 (R)-(+)-tryptophan methyl ester hydrochloride 
• 1173180-37-4 (S)-2-[(R)-3-(1H-indol-3-yl)-2-(4-oxo-4H-quinazolin-3-yl)-proprionylamino]propionic acid methyl ester 
• 1190111-93-3 (R)-3-(1H-indol-3-yl)-2-(4-oxo-4H-quinazolin-3-yl)-propionic acid methyl ester 
• 1602783-27-6 (S)-2-[(S)-3-(1H-indol-3-yl)-2-(4-oxo-4H-quinazolin-3-yl)propionylamino]propionic acid methyl ester 
• 1602783-25-4 methyl (S)-{2-[(S)-3-(1H-indol-3-yl)-2-(2-nitrobenzamido)propanamido]propanoate} 
• 610-14-0 2-nitrobenzyl chloride 
• 552-16-9 ortho-nitrobenzoic acid 
• 27261-93-4 (S)-3-(1H-indol-3-yl)-2-(2-nitrobenzamido)propanoic acid 

Relevant articles and documents

Synthesis and bioactivity studies of covalent inhibitors derived from (-)-Chaetominine

We reported herein the synthesis and bioactivity studies of compounds derived from the natural product (-)-Chaetominine (6). The key feature of these compounds is the incorporation of electrophilic groups that are capable of forming covalent bonds with the cysteine or threonine residues of cellular proteins. The cell growth inhibition activities of these derivatives of 6 were tested in four cancer cell lines, i.e. a leukemia cell line K562, a multiple myeloma cell line MM1.S, an acute myeloid leukemia cell line MV4-11, and a colon cancer cell line RKO. The data show that cellular growth inhibition IC50 values of 29, an acrylamide-containing molecule, are 9-17 folds more potent than that of 6, while other acrylamide-containing compounds are much less potent, suggesting 29 might have covalent interactions with cellular target proteins. Collectively, incorporation of an acrylamide moiety into 6 is a good strategy to improve its cell growth inhibition activity in cancer cell lines.

Biomimetic synthesis of (-)-chaetominine epimers via copper-catalyzed radical cyclization

Synthetic endeavors toward (-)-chaetominine via copper-catalyzed radical cyclization are reported. Both of the pyrido[2,3,b]-indole ring (C ring) and imidazolidinone (D ring) are efficiently constructed in one-pot manner. It's unveiled that the newly form

Complexity generation by chemical synthesis: A five-step synthesis of (-)-chaetominine from l-tryptophan and its biosynthetic implications

We demonstrated, for the first time, that on the basis of chemistry principles, the hexacyclic peptidyl alkaloid (-)-chaetominine (1) can be synthesized in a straightforward manner from l-Trp. The approach features the efficient generation of molecular complexity via a tandem C3/C14 syn-selective epoxidation (dr = 3:2)-annulative ring-opening reaction and a regioselective epimerization at C14. The successful production of (-)-chaetominine (1) from l-Trp could be helpful for revealing how the configuration of l-tryptophan becomes inverted in the biosynthetic pathway of (-)-chaetominine (1). This journal is the Partner Organisations 2014.